Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.

Abstract:

INTRODUCTION:Irritable bowel syndrome (IBS) treatment is challenging physicians because of its multifactorial physiopathology. In particular, abdominal pain and diarrhea management lack one unique effective pharmacological remedy. Opioid receptors, present in the central nervous system (CNS) and the enteric nervous system (ENS), are involved in visceral sensitivity and gastrointestinal motility control. To date only a few opioid receptor modulators are currently in use for the treatment of IBS but with dosage limitations due to the early development of severe constipation. AREAS COVERED:In this drug evaluation manuscript we review the irritable bowel syndrome therapeutic needs and chemistry, pharmacokinetics and -dynamics, clinical study results with the new opioid receptor ligand eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). EXPERT OPINION:Eluxadoline shows a peculiar pharmacological profile with μ-opioid agonism and δ-opioid antagonism actions. Its efficacy over placebo for the treatment of abdominal pain and diarrhea in IBS-D has been demonstrated in short- and long-term clinical studies in humans. Its safety has been evaluated in the same studies. Interestingly, eluxadoline showed a low rate of constipation development in IBS patients in comparison with known effects of other opioid receptor modulators. Patients with a history of acute pancreatitis should not be treated with eluxadoline.

authors

Scarpellini E,Laterza L,Ianiro G,Tack J,Abenavoli L,Gasbarrini A

doi

10.1080/14656566.2016.1182982

subject

Has Abstract

pub_date

2016-07-01 00:00:00

pages

1395-402

issue

10

eissn

1465-6566

issn

1744-7666

journal_volume

17

pub_type

杂志文章,评审
  • Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis.

    abstract::The recently published Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) assessed the efficacy and safety of abaloparatide (80 µg daily subcutaneous) (ABL) vs placebo during 18 months, in postmenopausal osteoporosis. Teriparatide (20 µg daily subcutaneous) (TPD) was used as an open label active comparator...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2017.1395021

    authors: Reginster JY,Al Daghri NM,Bruyere O

    更新日期:2017-12-01 00:00:00

  • Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis.

    abstract::The introduction of anti-TNFalpha therapy into the field of rheumatology has led to dramatic improvements in patient care, perhaps the most remarkable being in the management of ankylosing spondylitis. As experience with these compounds grows, their place in therapeutic strategy is becoming clearer, and it has been po...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.7.869

    authors: Zochling J,Braun J

    更新日期:2006-05-01 00:00:00

  • Radiocontrast-induced nephropathy and percutaneous coronary intervention: a review of preventive measures.

    abstract::Injectable and absorbable contrast media for the use in radiology, all of which contains iodine as an essential component, has been, and continues to be, one of the main sources of agents which cause hospital-acquired renal failure. Although numerous methods have been explored to prevent renal contrast damage, radioco...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.5.639

    authors: Mintz EP,Gruberg L

    更新日期:2003-05-01 00:00:00

  • Photodynamic therapy using 5-aminolaevulinic acid for the treatment of dysplasia in Barrett's oesophagus.

    abstract:BACKGROUND:5-Aminolaevulinic acid (ALA) is the naturally occurring metabolic precursor of an endogenously formed photosensitiser, protoporphyrin IX. It is used topically to treat benign and malignant skin disorders by a process called photodynamic therapy (PDT). Recently, data are emerging on its systemic use in the tr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.5.851

    authors: Dunn J,Lovat L

    更新日期:2008-04-01 00:00:00

  • Oxybutynin gel for the treatment of overactive bladder.

    abstract:INTRODUCTION:Overactive bladder (OAB) is a common condition that has a profound impact on an individual's overall health and quality of life. Muscarinic receptor antagonists are the mainstay of oral pharmacotherapy for OAB. While all of the medications in this class are significantly more effective than placebo, they a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.688953

    authors: Gomelsky A,Dmochowski RR

    更新日期:2012-06-01 00:00:00

  • Recent advances in the medical therapy of Crohn's disease in childhood.

    abstract::Crohn's disease (CrD) is characterised by an ongoing inflammatory response in the gut, in the absence of an obvious trigger. The treatment of CrD in children, during relapse and remission, requires special consideration of growth and development. This review addresses the use of present medical management strategies, ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.15.2553

    authors: Bremner AR,Beattie RM

    更新日期:2007-10-01 00:00:00

  • 72nd Meeting of the American Heart Association. November 1999, Atlanta, Georgia, USA.

    abstract::The American Heart Association annual meeting must be one of the largest scientific gatherings, attracting over 30,000 delegates. The meeting at the end of last year was held in Atlanta, USA, the 2000 meeting will be in New Orleans, USA. The following highlights represent my own interests. ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type:

    doi:10.1517/14656566.1.3.581

    authors: Lunnon MW

    更新日期:2000-03-01 00:00:00

  • Evaluation of injection force of three insulin delivery pens.

    abstract:OBJECTIVE:Reduced injection force is among the modifications to the Next Generation FlexPen (NGFP). This force was compared with two other prefilled pens: SoloStar (SS) and KwikPen (KP). RESEARCH DESIGN/METHODS:The injection force of the pens was measured, with either a BD Micro-Fine 31G thin-wall needle, or a NovoFin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656560903018929

    authors: Asakura T,Seino H,Kageyama M,Yohkoh N

    更新日期:2009-06-01 00:00:00

  • Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies.

    abstract:INTRODUCTION:Colorectal cancer (CRC) is the third most common cancer in the western world and also in Japan. The key factors in curing CRC are early detection, surgery and adequate adjuvant chemotherapy if needed. AREAS COVERED:Based on the results of following pivotal adjuvant trials, FOLFOX or XELOX are considered s...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1145665

    authors: Tsuji Y,Sugihara K

    更新日期:2016-01-01 00:00:00

  • Platelet glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions: a pharmacological and clinical review.

    abstract::One of the most significant advances of the last decade has been the development of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors. A large series of randomised, controlled clinical trials of these agents have shown a significant reduction in ischaemic events, not only in acute coronary syndrome patients, but...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.2.335

    authors: Anne G,Gruberg L

    更新日期:2004-02-01 00:00:00

  • The role of infectious agents in pulmonary and systemic vascular disease.

    abstract::With emphasis on the pulmonary circulation, three general types of vascular disease are discussed: fibroproliferative (atherosclerosis), cellular proliferative (endothelial neoplasms) and inflammatory (granulomatous vasculitis). The causes of these phenotypic responses are invariably multifactorial, but infectious age...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.7.1093

    authors: Egermayer P

    更新日期:2001-07-01 00:00:00

  • Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.

    abstract:INTRODUCTION:Venous thromboembolism (VTE) causes substantial morbidity and mortality worldwide. The traditional treatment of VTE, with an initial therapy with (low molecular weight) heparin or fondaparinux and a continued treatment with vitamin K antagonists, is effective but has limitations. AREAS COVERED:The current...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.999043

    authors: Vanassche T,Vandenbriele C,Peerlinck K,Verhamme P

    更新日期:2015-04-01 00:00:00

  • Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?

    abstract:INTRODUCTION:Historically, there were few effective and durable treatments for metastatic melanoma. Recently, mutation based targeted therapies have revolutionized treatment and outcomes for patients with metastatic melanoma. Specifically, inhibitors aimed at BRAF, NRAS, and C-KIT mutations are now commonly used in tre...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1299710

    authors: Turner MC,Rossfeld K,Salama AK,Tyler D,Beasley G

    更新日期:2017-04-01 00:00:00

  • Daily versus intermittent corticosteroids for the treatment of mild persistent asthma.

    abstract::Asthma is a chronic disease of the airways in which inflammation causes bronchial hyper-reactivity and attacks of wheezing, dyspnea and chest tightness that are triggered by various agents. It requires both acute treatment of the paroxistical respiratory symptoms with reliever medications and maintenance treatment, wh...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.7.9.1235

    authors: Antoniu SA

    更新日期:2006-06-01 00:00:00

  • Exemestane in postmenopausal women with early or advanced breast cancer: a review.

    abstract:IMPORTANCE OF THE FIELD:Inhibition of the aromatase enzyme in postmenopausal women reduces levels of estrogens, which is of therapeutic value in hormone-sensitive breast cancer. Exemestane is a third-generation steroidal irreversible inactivator of the aromatase enzyme used in early and advanced breast cancer for the t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.495945

    authors: Bertelli G,Gangadhara S

    更新日期:2010-08-01 00:00:00

  • Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.

    abstract:BACKGROUND:Chronic hyperglycemia has an adverse influence on beta-cell function, which is known as 'glucotoxicity'. Sodium-glucose cotransporter-2 (SGLT2) inhibitors lower the blood glucose concentration by enhancing urinary glucose excretion. This study was performed to clarify the influence of the SGLT2 inhibitor ipr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 临床试验,杂志文章

    doi:10.1080/14656566.2016.1261110

    authors: Nagai Y,Ohta A,Sada Y,Kato H,Tanaka Y

    更新日期:2017-01-01 00:00:00

  • Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.

    abstract:INTRODUCTION:Sorafenib is a novel oral bis-aryl urea compound that has proven survival benefit in patients with advanced hepatocellular carcinoma (HCC), for which several therapies are currently available with unsatisfactory results. Sorafenib is the first compound to demonstrate a significant effect on survival in HCC...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.546346

    authors: Guan YS,He Q

    更新日期:2011-02-01 00:00:00

  • Treating myoclonic epilepsy in children: state-of-the-art.

    abstract:INTRODUCTION:Myoclonic seizures can be observed in various clinical settings and different epileptic conditions, including some forms of both diopathic and symptomatic epilepsies. Relatively little has been written on treatment of myoclonic seizures. Some old antiepileptic drugs, such as valproate and some benzodiazepi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.800045

    authors: Striano P,Belcastro V

    更新日期:2013-07-01 00:00:00

  • Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis.

    abstract:AIM:To evaluate the efficacy and adverse effects of IDegLira and IGlarLixi treatment and to perform a comparison between two strategies. METHODS:The registration number is CRD42017053952. Randomized controlled trials of IGlarLixi treatment or IDegLira treatment compared with placebo or active hypoglycemic agents in ty...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/14656566.2017.1400011

    authors: Cai X,Gao X,Yang W,Ji L

    更新日期:2017-12-01 00:00:00

  • Intravesical therapy for bladder cancer.

    abstract:INTRODUCTION:Transurethral resection of bladder tumor (TURBT) is the gold standard initial diagnostic intervention for bladder cancer and provides diagnostic, therapeutic and prognostic benefit in non-muscle-invasive bladder cancer (NMIBC). However, TURBT alone is inadequate for optimal management of NMIBC, as patients...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1024656

    authors: Patel SG,Cohen A,Weiner AB,Steinberg GD

    更新日期:2015-04-01 00:00:00

  • From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch study.

    abstract:PURPOSE:To assess ocular surface status and tolerability after switching glaucoma patients from dorzolamide/timolol to brinzolamide/timolol fixed combination (FC). METHODS:Six-month, multicenter, open-label, prospective study that switched 72 patients from dorzolamide/timolol to brinzolamide/timolol FC. Intraocular pr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1517/14656566.2011.589384

    authors: Rossi GC,Pasinetti GM,Sandolo F,Bordin M,Bianchi PE

    更新日期:2011-11-01 00:00:00

  • Pharmacotherapy of postpartum depression: an update.

    abstract:INTRODUCTION:Postpartum depression (PPD) is a common and serious illness that affects up to 14% of women in the first month after childbirth. We present an update on the pharmacologic treatment of PPD, although there continues to be a lack of large, randomized controlled trials (RCTs). AREAS COVERED:A review of the li...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.911842

    authors: Kim DR,Epperson CN,Weiss AR,Wisner KL

    更新日期:2014-06-01 00:00:00

  • Therapeutic management of psychodermatological disorders.

    abstract:BACKGROUND:The skin and the brain interact through psychoneuroimmunoendocrine mechanisms and through behaviors that can strongly influence the initiation or flaring of skin disorders. OBJECTIVE:To obtain knowledge of these factors to assist in designing treatment plans for specific skin disorders. METHODS:Psychocutan...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.6.973

    authors: Shenefelt PD

    更新日期:2008-04-01 00:00:00

  • Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy.

    abstract::Introduction: Hypertrophic cardiomyopathy (HCM) is one of the most common genetic heart diseases and represents a leading cause of sudden cardiac death as well as a prevalent cause of heart failure and stroke. HCM is characterized by a very complex pathophysiology, consisting of heterogeneous clinical manifestations a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1702023

    authors: Spoladore R,Fragasso G,Pannone L,Slavich M,Margonato A

    更新日期:2020-02-01 00:00:00

  • Innovative therapies for neovascular age-related macular degeneration.

    abstract::Introduction: Investigational anti-VEGF treatments for neovascular age-related macular degeneration (nAMD) aim to improve visual outcomes and reduce treatment burden; these include long-acting agents, combination strategies, topical agents, sustained-release, and genetic therapies. Areas covered: The authors provide a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1636031

    authors: Al-Khersan H,Hussain RM,Ciulla TA,Dugel PU

    更新日期:2019-10-01 00:00:00

  • Transdermal oxybutynin: a new treatment for overactive bladder.

    abstract::Overactive bladder has been successfully treated with oral anticholinergic drugs such as oxybutynin chloride. Although oral oxybutynin has been effective in controlling urinary urge incontinence and in decreasing incontinence episodes, adverse events, particularly dry mouth, often cause patients to discontinue oral th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.12.2315

    authors: Davila GW

    更新日期:2003-12-01 00:00:00

  • Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives.

    abstract:INTRODUCTION:Glioblastoma, the most common malignant brain tumor, exhibits a poor prognosis with little therapeutic progress in the last decade. Novel treatment strategies beyond the established standard of care with temozolomide-based radiotherapy are urgently needed. AREAS COVERED:We reviewed the literature on gliob...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1176146

    authors: Seystahl K,Gramatzki D,Roth P,Weller M

    更新日期:2016-06-01 00:00:00

  • Lipid pharmacotherapy for treatment of atherosclerosis.

    abstract:INTRODUCTION:For more than two decades, lowering levels of low-density lipoprotein cholesterol has formed the cornerstone of management of patients with atherosclerotic cardiovascular disease. The substantial residual risk of clinical events in patients treated with statin therapy highlights the need to develop more ef...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.904287

    authors: Nicholls SJ,Pisaniello AD,Kataoka Y,Puri R

    更新日期:2014-06-01 00:00:00

  • Ziprasidone for maintenance treatment of bipolar I disorder in adults.

    abstract:INTRODUCTION:Antipsychotic drugs are increasingly used in the maintenance treatment of bipolar disorder. This review addresses the evidence supporting the use of one of these medications for this indication in order to place available data in perspective for the clinician. AREAS COVERED:The approval of ziprasidone for...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.2011.563237

    authors: Dubovsky SL,Dubovsky AN

    更新日期:2011-04-01 00:00:00

  • Efavirenz: a review.

    abstract::Efavirenz is a non-nucleoside reverse transcriptase inhibitor that in most treatment guidelines is recommended to be taken combined with two nucleoside analogue reverse transcriptase inhibitors, as a preferred first-line regimen for the treatment of HIV-1 infection. The antiretroviral efficacy of efavirenz-based combi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.6.851

    authors: Vrouenraets SM,Wit FW,van Tongeren J,Lange JM

    更新日期:2007-04-01 00:00:00